Loading...
 

Volume 31, Issue 2, June 2020




Sign in to download the Issue in PDF format.

Mediterr J Rheumatol 2020;31(Supp 1):137-44
Under Development JAK Inhibitors for Dermatologic Diseases
Authors Information

1st Dermatology Department, School of Medicine, Aristotle University, Thessaloniki, Greece

Abstract

Molecular targeting therapies represent a new exciting era in dermatology. A promising novel drug class, subject of intense research, is Janus kinase (JAK) inhibitors. Multiple cytokine receptors signal through the Janus kinase and signal transducer and activator of transcription (STAT) pathway. The pathway plays a central role in innate and adaptive immunity, and haematopoiesis. The understanding of the contribution of JAKs to the immunologic processes of inflammatory diseases led to the development of JAK inhibitors, initially for rheumatologic and hematologic diseases. Soon, their efficacy in some dermatologic conditions was also demonstrated, and today their role as therapeutic agents is thoroughly researched, mainly in atopic dermatitis, psoriasis, vitiligo, and alopecia areata.

JAK inhibitors can be administered orally or used topically. As they are relatively new treatment modalities in dermatology, many questions concerning their efficacy and safety remain unanswered. Data from ongoing trials are eagerly awaited.

Here, we summarize under development JAK inhibitors for dermatologic diseases.

https://doi.org/10.31138/mjr.31.1.137

This work is licensed under a Creative Commons Attribution 4.0 International License (CC-BY).

©Sideris N, Vakirlis E, Tsentemeidou A, Kourouklidou A, Ioannides D, Sotiriou E.